Opioids represent the most-utilized drug class in workers’ compensation, making first-line overdose treatment
more critical for injured workers than ever.
Countering Overdose Effects
Both Narcan® Nasal Spray and Evzio® auto-injector are FDA approved as “take home” naloxone opioid antagonists that reverse the toxic effects of opioids. While therapeutically equivalent, their costs vary widely.
In a six-month analysis of Evzio to Narcan conversion efforts,
First Script was able to successfully stop 88% of Evzio scripts
from filling and saved our clients $64,080.
Find out why studies of efficacy, ease of use, and cost comparisons recommend Narcan® Nasal Spray as a more cost-effective, first-line treatment for managing opioid overdose risk.